Medgenics Share Discussion Threads

[sicilian_kan] 06/7/2011 15:08

News now added into the header.

[sicilian_kan] 06/7/2011 15:06

Note that:

1. Unlike the last extension, Baxter are paying for the studies now!

2. These are described as confirmatory studies. This means that Medgenics has now reached the correct target levels for Factor VIII delivery, the most difficult protein that there is.

3. Assuming that these studies confirm their current studies, there will be an exclusivity option payment and then potentially a mega deal within 6 months.

[sicilian_kan] 06/7/2011 15:03

News out within minutes of starting the thread!

I need to add a news thread into the header. Anyhow, here goes:

RNS Number : 8915J

Medgenics Inc

06 July 2011

MEDGENICS EXTENDS COLLABORATION WITH BAXTER ON DEVELOPMENT OF FACTOR VIII BIOPUMP

MISGAV, Israel and VIENNA, Va. (July 06, 2011) - Medgenics, Inc. (NYSE AMEX: MDGN and AIM: MEDU, MEDG) announces an extension of its agreement with Baxter Healthcare Corporation for the joint development of the Factor VIII Biopump.

Under the extension, confirmatory studies will be conducted implanting Factor VIII Biopumps in mice. Baxter will bear the costs of these studies including the preparation and delivery of the necessary Biopumps. During the extended agreement, which will expire by September 30, 2011, Baxter has the opportunity, to exercise an exclusive option for 6 months to negotiate with Medgenics an agreement for commercialization of the Biopump Factor VIII technology.

"During recent months Medgenics has made considerable progress with the performance of our Biopump technology, and we are delighted to be moving forward with our collaboration with Baxter, the global leader in hemophilia treatments," stated Andrew L. Pearlman, Ph.D., President and CEO of Medgenics. "We look forward to completing these confirmatory studies and expect that they will validate the ability of our Biopump to produce clinically relevant levels of Factor VIII."

[sicilian_kan] 06/7/2011 14:51

New thread with header at:



Please use that thread now in future.

[sicilian_kan] 06/7/2011 14:50

Welcome to the new thread. Any requests for the header, please let me know.

[sicilian_kan] 05/7/2011 15:42

Yep, good news again. These shares will hit the big time in the next 12 months, possibly even in the next 2-6 months.

[jammytass] 05/7/2011 15:40

MEDGENICS NAMES CLARENCE "BUTCH" DELLIO AS CHIEF OPERATING OFFICER



Experienced Biotech Executive Provides Strategic Management and Manufacturing Expertise

[sicilian_kan] 01/7/2011 08:11

Nice small rise yesterday with a few tickups, but bear in mind, for this share to match the US one (and they have the same nominal value so should be valued the same), then the share price here on MEDU will need to reach £2.56 (US shares are trading at $4.098). At £1.975, MEDU is a bargain and should rise 25% more to partity with the US stock.

[sicilian_kan] 29/6/2011 10:00

Andy Pearlman said at the proactive presentation last week, by the way, something along the lines of Isaac Blech decided to get involved in Medgenics as he thought it might become the next Genentech.

FYI, Isaac Blech is now on Medgenics' board. He holds 17.1% of the company having bought big time in the US IPO and he has founded 7 biotech companies with a combined value now of over $30bn. So his saying that Medgenics could become the next Genentech is a serious comment.

Could even become the tag line to the next ADVFN thread perhaps. "Medgenics - The Next Genentech?"

[jammytass] 24/6/2011 06:06

sicilian > many thanks, lets hope its the start of big moves for this cmpy

[sicilian_kan] 23/6/2011 22:35

Presentation available. Andy Pearlman gave an excellent presentation that generated much interest in the room from people who were not aware of the company. An 8 minute interview will also go up on the web soon.

[sicilian_kan] 17/6/2011 07:17

Proactive article out:



Says:

1. "rivals with competing but less effective technology are trading on much ritzier ratings."

2. "In one patient EPODURE is still working some 30 months after the Biopump was first inserted, while most of the others are enjoying relief from their symptoms six to 12 months after first receiving the implant."

3. Re INFRADURE, Medgenics "hopes to "have in the first patients by the end of 2011""

4. Re HEMODURE "we have developed Biopumps which are producing very nice quantities of Factor VIII. The Medgenics boss believes Baxter will extend the agreement, but cannot yet say if they will proceed towards a full commercial licensing agreement. "We are hopeful they will go forward with us," he adds."

5. "the company is talking to other potential partners as EPODURE moves towards phase IIb trials. This may alleviate the need to come to the market for more cash" which is expected to fund the company past Q1 11 after which it will consider its options. "Successfully negotiating a second partnership with a strategic partner could provide a huge catalyst for the rerating of the stock". "We are having some rather significant discussions with potential strategic partners," he reveals, "But it is premature to say more than that."

6. The m/cap pales in comparison with Amex-listed Prolor Biotech that has a $350m m/cap, has only just started trials and hopes to make injections last 3-5x (i.e. 3-5 weeks), whilst Medgenics is achieving 6-30 months. "We are on AIM, but we have a technology that is arguably much better, we have substantial data showing that it actually works in treating patients, and we have been collaborating with a major healthcare company"

8. "There had been recent selling pressure as warrants in the IPO "muddied the water a little and created a clear arbitrage opportunity that may have helped depress the price". In addition, the Company has only just come out of a standard "quiet period" following the AMEX listing, during which it could not actively promote the company and its stock."

9. "Hopefully, an update on the EPODURE trial in the coming month or two will report completion of the recruitment and treatment of the final patients in phase I/II trial, and will maintain the momentum."

10. By Q1 11, they are also targetting IND approval from the US FDA for the Phase IIB anaemia trials, the human INFRADURE trials an a HEMODURE update.

[sicilian_kan] 17/6/2011 07:03

Note that the current MEDU share price is worth $2.73, but the US AMEX share price is now at $3.40 / share. The MEDU shares are therefore 25% undervalued compared to their US stock. Makes and excellent buying opportunity as on any takeover, all shares are sold at the same price and this will be relative to the US price.

[sicilian_kan] 13/6/2011 19:07

Agreed jt. There is the Baxter news and the trial results, both now overdue.

[jammytass] 13/6/2011 15:54

share price should start to move north real soon

[sicilian_kan] 02/6/2011 22:37

You're welcome.

[sicilian_kan] 02/6/2011 16:30

Of course, they have just raised $10m too, which should be taken into account.

[sicilian_kan] 02/6/2011 16:25

According to the 4 May 11 press releasee, there are 9,551,567 shares in issue. The US stock is trading at $3.21 / share. Taking that as a ball park, I make the market cap around £19m, but there will be a little fluctuation if one does an actual calculation based on US/and AIM * 2 prices.

I think the US spread is less from recollection. Might be worth buying that if it is the case. But at the end of the day, this is share that will either multibag this year or will drift further, so the spread will not be the killer. If the imminent trial results are good and/or if they get a long term hemodure deal with Baxter, it should be multibag.

[mustau] 02/6/2011 15:26

Can someone confirm the true Market cap?

Looking at this but the spread is a killer.